PL2558095T3 - Związek organiczny, przeznaczony do stosowania w leczeniu raka wątroby - Google Patents

Związek organiczny, przeznaczony do stosowania w leczeniu raka wątroby

Info

Publication number
PL2558095T3
PL2558095T3 PL11715691T PL11715691T PL2558095T3 PL 2558095 T3 PL2558095 T3 PL 2558095T3 PL 11715691 T PL11715691 T PL 11715691T PL 11715691 T PL11715691 T PL 11715691T PL 2558095 T3 PL2558095 T3 PL 2558095T3
Authority
PL
Poland
Prior art keywords
treatment
organic compound
liver cancer
liver
cancer
Prior art date
Application number
PL11715691T
Other languages
English (en)
Inventor
Diana Graus-Porta
Herbert Schmid
Michael Shi
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL2558095T3 publication Critical patent/PL2558095T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL11715691T 2010-04-16 2011-04-14 Związek organiczny, przeznaczony do stosowania w leczeniu raka wątroby PL2558095T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32493610P 2010-04-16 2010-04-16
PCT/EP2011/055906 WO2011128403A1 (en) 2010-04-16 2011-04-14 Organic compound for use in the treatment of liver cancer
EP11715691.9A EP2558095B1 (en) 2010-04-16 2011-04-14 Organic compound for use in the treatment of liver cancer

Publications (1)

Publication Number Publication Date
PL2558095T3 true PL2558095T3 (pl) 2019-06-28

Family

ID=44260208

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11715691T PL2558095T3 (pl) 2010-04-16 2011-04-14 Związek organiczny, przeznaczony do stosowania w leczeniu raka wątroby

Country Status (17)

Country Link
US (1) US8741903B2 (pl)
EP (1) EP2558095B1 (pl)
JP (1) JP2013525291A (pl)
KR (1) KR20130073873A (pl)
CN (1) CN102844031A (pl)
AU (1) AU2011239999B2 (pl)
BR (1) BR112012026289A2 (pl)
CA (1) CA2793779A1 (pl)
DK (1) DK2558095T3 (pl)
ES (1) ES2707625T3 (pl)
HU (1) HUE042535T2 (pl)
MX (1) MX2012012051A (pl)
PL (1) PL2558095T3 (pl)
PT (1) PT2558095T (pl)
RU (1) RU2012148710A (pl)
TR (1) TR201819653T4 (pl)
WO (1) WO2011128403A1 (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
SG11201408238WA (en) 2012-06-13 2015-01-29 Incyte Corp Substituted tricyclic compounds as fgfr inhibitors
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
EA035095B1 (ru) 2013-04-19 2020-04-27 Инсайт Холдингс Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
EA201691846A1 (ru) * 2014-03-17 2016-12-30 ИНКУРОН, ЭлЭлСи Композиции и способы лечения рака печени
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CR20170390A (es) 2015-02-20 2017-10-23 Incyte Holdings Corp Heterociclos biciclicos como inhibidores de fgfr
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
WO2019213506A1 (en) 2018-05-04 2019-11-07 Incyte Corporation Salts of an fgfr inhibitor
SG11202010636VA (en) 2018-05-04 2020-11-27 Incyte Corp Solid forms of an fgfr inhibitor and processes for preparing the same
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CR20220169A (es) 2019-10-14 2022-10-27 Incyte Corp Heterociclos bicíclicos como inhibidores de fgfr
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP2023505258A (ja) 2019-12-04 2023-02-08 インサイト・コーポレイション Fgfr阻害剤としての三環式複素環
CA3162010A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE309996T1 (de) 2000-09-11 2005-12-15 Chiron Corp Chinolinonderivate als tyrosin-kinase inhibitoren
EP1539754A4 (en) 2002-08-23 2009-02-25 Novartis Vaccines & Diagnostic BENZIMIDAZOLE QUINOLINONES AND USES THEREOF
CN1960731B (zh) * 2004-02-20 2011-12-07 诺华疫苗和诊断公司 调节炎性和转移过程的方法
PT1845990E (pt) * 2005-01-27 2011-12-23 Novartis Vaccines & Diagnostic Tratamento de tumores metastatizados
SI1845990T1 (sl) * 2005-01-27 2012-01-31 Novartis Vaccines & Diagnostic Zdravljenje metastaziranih tumorjev
WO2006127926A2 (en) 2005-05-23 2006-11-30 Novartis Ag Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts
PE20091628A1 (es) 2008-03-19 2009-11-19 Novartis Ag Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona

Also Published As

Publication number Publication date
US20130123272A1 (en) 2013-05-16
EP2558095A1 (en) 2013-02-20
AU2011239999B2 (en) 2014-04-03
PT2558095T (pt) 2019-01-29
HUE042535T2 (hu) 2019-07-29
CN102844031A (zh) 2012-12-26
JP2013525291A (ja) 2013-06-20
MX2012012051A (es) 2012-11-22
US8741903B2 (en) 2014-06-03
TR201819653T4 (tr) 2019-01-21
WO2011128403A1 (en) 2011-10-20
RU2012148710A (ru) 2014-05-27
KR20130073873A (ko) 2013-07-03
DK2558095T3 (en) 2019-01-14
ES2707625T3 (es) 2019-04-04
CA2793779A1 (en) 2011-10-20
EP2558095B1 (en) 2018-10-24
AU2011239999A1 (en) 2012-11-08
BR112012026289A2 (pt) 2016-07-12

Similar Documents

Publication Publication Date Title
PT2558095T (pt) Composto orgânico para utilização no tratamento do cancro hepático
HUS2100055I1 (hu) IBAT-inhibitorok májbetegségek kezelésére
ZA201207574B (en) Phytocannabinoids in the treatment of cancer
ZA201300567B (en) Methods and compositions for liver cancer therapy
EP2571361A4 (en) PYRAZOLOPYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
EP2542081A4 (en) COMPOSITIONS FOR CANCER TREATMENT
GB201115711D0 (en) Phyto-cannabinoids for use in the treatment of cancer
IL251083B (en) Compounds and preparations for the treatment of cancer
EP2688594A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
IL222958A0 (en) Cancer treatment
SI2605764T1 (sl) Sestavki za zdravljenje raka
EP2608671A4 (en) COMPOUNDS USED IN THE TREATMENT OF CANCER
EP2635121A4 (en) ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER
EP2547368A4 (en) METHOD AND COMPOSITIONS FOR CANCER TREATMENT
GB201718726D0 (en) Phytocannabinoids in the treatment of cancer
GB201011073D0 (en) Composition for the treatment of acne vulgaris
GB201301168D0 (en) Cancer treatment
HUP1000688A2 (en) Use of trifluoro-phthalimides in the treatment of cancer
HUE051937T2 (hu) IBAT-inhibitorok májbetegségek kezelésére